Ketamine International Conference 2024

Conference Program Day 1
Monday, 25th March

11.00 | Registration

11.30

Anatomy of Melancholy – revision of neuroanatomy relevant to depression

Speaker: Laith Alexander (Kings College London)

12.00 | Lunch – Early Career Researchers Lunch (location TBC)

12.45

Welcome and Introduction

Speaker: Rupert McShane (University of Oxford, UK)

12.55

Lateral habenula and social dominance

Speaker: Hailan Hu (Zhejiang University, China)

13.55

Implementation of emerging psychedelics: models of support and interventional psychiatry

Speaker: Steve Levine (COMPASS Pharmaceuticals, USA)

14.25

RCT of ketamine for OCD

Speaker: Peter van Roessel (Stanford University, USA)

15.00 | Tea

15.30

Addiction potential of ketamine enantiomers and metabolites, and of esmethadone

Speaker: Mike Michaelides (National Institute on Drug Abuse, USA)

16.00

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine (the GO-MARK study)

Speaker: Luke Jelen (King’s College London, UK)

16.30

Opioid use diminishes placebo antidepressant response independently of pain in a ketamine depression trial

Speaker: Theresa Lii (Stanford University, USA)

|

18.00

Debate at Holywell Music room followed by reception at the Weston Library

This house believes that oral home treatment with ketamine could be widely and safely used for the treatment of resistant depression

Speakers For:

Rupert McShane (University of Oxford, UK) TBC,

Robert Schoevers (Groningen University, The Netherland) TBC

|

Speakers Against:

Alan Schatzberg (Stanford University, USA),

Zoe Cormier (Author and Journalist, UK)

| Chair: | TBC

Conference Program Day 2
Tuesday, 26h March – morning

09.00

Pilot RCT of ketamine + Written Exposure Therapy for PTSD

Speaker: Adriana Feder (Icahn School of Medicine at Mount Sinai, USA)

09.30

Comorbid PTSD and childhood trauma: impact on ketamine’s efficacy in TRD

Speaker: Danica Johnson (University of Toronto, Canada)

10.00

Prucalopride (5HT4a agonist) plus ketamine: additive effects on stress

Speaker: Christine Denny (Columbia University, USA)

10.30 | Coffee Break

11.00

Opioid-dependent mechanisms of ketamine antidepressant action

Speaker: Alan Schatzberg (Stanford University, USA)

11.40

EEG gamma oscillations as a prognostic marker for IV ketamine in TRD

Speaker: Sanjay Mathew (Baylor College of Medicine, USA)

12.10

Targeted ketamine delivery to the thalamus using ultrasound

Speaker: Raag Airan (Stanford University, USA)

12.30 | Lunch

Conference Program Day 2
Tuesday, 26h March – afternoon

13.15

Ketamine vs. ECT: implications for clinical practice, policy and future research

Speaker: Amit Anand (Harvard Medical School, USA)

13.45

Machine learning to predict response to ECT vs (es)ketamine

Speaker: Michael Henry (Harvard Medical School, USA)

14.15

RCT of ketamine for depression in Parkinson’s disease

Speaker: Sophie Holmes (Yale University)

14.35

Short talk sessions

IV ketamine: RWE following induction- Speaker: Patrick Oliver (MindPeace Clinics, USA)

IV esketamine in TRD – RWE following induction – Speaker: Tiago Gill (Centro de Cetamina, Brazil)

Predictors of ketamine response in 1047 patients: machine learning and RWE – Speaker: George Wohlfold (University of Virginia, USA)

15.15 | Tea

15.45

Title TBC

Speaker: Robert Schoevers (University of Groningen, The Netherlands)

16.15

Mesmer, ketamine and cardiac surgery: mechanisms of non-specific effects

Speaker: Gerard Sanacora (Yale Universiy, USA)

|
18.45 | Pre-dinner drinks – Fellows Garden, Exeter college
19.30 | Conference Dinner – Exeter College Dining Hall

Conference Program Day 3
Wednesday, 27h March – morning

09.00

Mouse model of anorexia: effects of ketamine in adults and adolescents

Speaker: Chiye Aoki (New York University, USA)

09.30

RCT of dextromethorphan vs psilocybin: effects in healthy volunteers with history of hallucinogen use

Speaker: David Mathai (Johns Hopkins, USA)

10.00

Psilocybin and ketamine: two side of the same coin?

Speaker: David Nutt (Imperial College London, UK)

10.30 | Coffee Break

11.00

R-Ketamine for Treatment Resistant Depression

Speaker: David Feifel (University of California, USA)

11.30

Title TBC

Speaker: Celia Morgan (University of Exeter, UK)

12.00

Bladder symptoms: prospective long-term data in 295 patients

Speaker: Rupert McShane (University of Oxford, UK)

12.30

Lunch

Conference Program Day 2
Wednesday, 27h March – afternoon

13.15

Dose finding study of prolonged release oral ketamine formulation

Speaker: Hans Eriksson (Ketabon, USA)

13.45

Keticap immediate release, abuse deterrent: Phase 1 data

Speakers: Mario Juruena (Kings College, UK)

14.15

Pilot RCT of ethosuximide in TRD: efficacy and safety

Speakers: Shaohua Hu (Zhejiang University, China)

14.35

Short talk sessions

IV ketamine: RWE following induction- Speaker: Patrick Oliver (MindPeace Clinics, USA)

EEG dissociation – Speaker: Marco Fabus (University of Oxford, UK)

Influence of ketamine on the effect of expectations on perceptual and emotional learning – Speaker: Lilian Weber (University of Oxford, UK)

Talk TBC – Speaker: TBC

15.15 | Tea

15.45

Leveraging the diverse properties of ketamine to address psychiatric challenges

Speaker: Elias Dawkar (Columbia University, USA)

16.15

Long-term safety and durable efficacy of esketamine in TRD and ESCAPE-TRD

Speaker: Wayne Drevets (Janssen Pharmaceutical, USA)

16.45

Closing remarks

Speaker: Rupert McShane, University of Oxford, UK